Article Text

Download PDFPDF

4CPS-180 Sacituzumab-govitecan in metastatic triple-negative breast cancer: comparison of our data to the ascent trial after 2 years of experience
  1. L Dho,
  2. A Maire,
  3. C Levenbruck,
  4. J Coussirou,
  5. D Zerbib,
  6. F De Crozals
  1. Institut Sainte Catherine, Pharmacy, Avignon, France


Background and Importance Sacituzumab-govitecan (SG) is an antibody-drug conjugate used in metastatic triple-negative (TN) breast cancer (BC). Adverse events (AEs) described in the physical desk reference are often based on an over selected population and can be more severe in real-life conditions.

Aim and Objectives After two years of practice, what are the most common AEs in our hospital and what did we do to prevent them?

Material and Methods We did a retrospective study that included all our patients with TNBC from May 2021 to July 2023, and compared our results to the Ascent Trial (AT). We monitored their general state, the number of treatments and metastatic sites they had before the first cycle, the types and grades of AE and how we managed them.

Results Our 25 patients’ medium age was 62 (AT = 54). In our study, the median number of lines before SG was four, just like in the AT. 56% of our patients had a performance status (ECOG) 0 (AT = 43%), 32% were ECOG 1 (AT = 57%) and 12% were ECOG 2.

Regarding AEs alone, 21 out of our 25 patients experienced them, mainly after 15,2 weeks of treatment (around the fifth cycle). The average dose-intensity at the time of AEs was 1120 ± 300 mg/21 days. 56% of our patients had neutropenia (AT = 63%) but we had less grade 3 or higher (G3+) neutropenia compared to the AT (24% versus 51%). 68% of our patients received growth factors (AT = 49%). 52% of our patients experienced asthenia (AT = 45%), 44% nausea (AT = 57%) and 52% diarrhoea (AT = 59%) among which 20% were a G3+ (AT = 10%).

Dose reductions were more frequent in our group compared to the AT (60% versus 22%). 28% had to skip at least one cycle and three patients had to change line because of AE.

Conclusion and Relevance Our study’s AEs were similar to the ones described in the AT. However, we observed more G3+ diarrhoea and less G3+ neutropenia. Since June 2023, atropine has been used as systematic premedication to prevent severe diarrhoea. Our centre also resorts to growth factor injections more frequently.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.